Risk-sharing Arrangements

This blog contains a selection of the posters and presentations given by OHE at ISPOR Philadelphia in May 2015.

This post is the second of a two part summary of OHE’s scheduled activity at ISPOR Philadelphia 2015.

Medicines Adaptive Pathways: A Practical Strategy to Improve Patient Access to Medicines?
 
In September 2014 the Centre for Innovation in Regulatory Science held a workshop with invited regulators, health technology assessment (HTA) bodies and...

ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. This is the second of two blog posts that outlines OHE’s involvement. (The first blog is available...

Adrian Towse, currently President of ISPOR, contributed to two session at the recent ISPOR Asia-Pacific conference.

Using HTA to maximise health system performance: Health technology assessment (HTA) is familiar as a technique for...

Best practices for performance-based risk-sharing arrangements in health care are described in detail in this new ISPOR report, developed by a task force co-chaired by Professor Lou Garrison, University of Washington and Visiting Senior Research Fellow at the OHE, and Professor Adrian Towse, Director of the OHE. The report appeared in late August in Value in Health. The idea of paying only for health interventions that work at least as well as expected is intuitively attractive.

OHE was involved in several sessions at the 9th World Congress of the International Heath Economics Association (iHEA). Prof Adrian Towse, OHE’s Director, and Prof Lou Garrison, OHE Visiting Senior Research Fellow for 2012-13 and a professor at the University of Washington, took part in a session focusing on barriers to utilisation and delivery of health service in developing countries.

Dr Jorge Mestre-Ferrandiz, OHE's Director of Consulting, was a recent guest lecturer at Imperial College London. His comprehensive presentation covered the gamut of issues that influence the rate and direction of R&D for medicines, including regulatory approval requirements, the patent system, the economics of R&D, the roles of the public and private sectors, “push” and “pull” incentives, and the influence of capital markets.

Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on whether/how well it actually works. Programmes typically include data collection and either implicitly or explicitly link pricing, reimbursement and/or revenue to what the data show.

To celebrate its 50th Anniversary, OHE held a conference this week, The Challenges and Economics of Drug Development in 2022, which explored the likely evolution of the key aspects of drug development over the next ten years. The conference was attended by over 100 participants from the public and private sectors; speakers and panellists included leaders from drug regulatory agencies, health technology assessment (HTA) groups, payers, the pharmaceutical industry, private foundations, and academia.

Pages

Subscribe to RSS - Risk-sharing Arrangements